Impedimed's (IPD) latest announcement maintains its track-record of over-delivery which has now driven the twelve-month gain to 330%
Impedimed's (IPD) latest announcement maintains its track-record of over-delivery which has now driven the twelve-month gain to 330%. With a market cap of $275M, it is now the ASX's fourth largest biotech. It has a strong institutional register which includes Fidelity, and a cash balance of $38mil, compared to this time last year, when its market cap was $39M and cash was at just $4.5M. Driving this transformation has been exceptional performance from Impedimed's management team. Last year, L-Dex received an FDA approval and reimbursement code that expanded its potential market four-fold. In November, Impedimed secured reimbursement of $112 per test - while the market expected $30-40. Most recently, the company has announced the addition of two, prominent community oncology clinics to the pilot launch of its 'L-Dex lymphoedema test'. The company has now signed a total of three sites and was aiming to have signed six by mid-2015. This performance is set to continue as management's real strength and expertise is in selling devices as the pilot launch is now showing. Updated research here: (VIEW LINK)
Canaccord Genuity Group is a leading independent, full-service financial services firm. Canaccord Genuity has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual,...
No areas of expertise